Agilent to Buy Cartagenia | GenomeWeb

NEW YORK(GenomeWeb) – Agilent Technologies and Cartagenia said today that Agilent will acquire Cartagenia for an undisclosed sum.

The acquisition will provide Agilent with software solutions for its clinical genetics and molecular oncology customers, while providing stronger support and services for Cartagenia's clients, Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.